⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

January 1, 2026Journal of Crohn s and Colitis

P1301 Time-trend and forecasting of the economic impact of inflammatory bowel disease in catalonia: a population-based analysis

E Brunet B Garcia Sague E Vela C Pontes L Melcarne Luis Enrique Frisancho Laura Patricia Llovet P Pedragal-Pascual A Puy Guillen Sergio Lario M J Ramírez-Lázaro A Villoria Ferrer S Coward G Kaplan X Calvet Calvo

View at Publisher

Ask AI

Bookmark

Share

Key Points

This analysis aims to assess the trends and future forecasting of healthcare expenditures related to inflammatory bowel disease in Catalonia.
Analyzed expenditure data from the Catalan Health Surveillance System covering 8 million inhabitants.
Included IBD patients with prescriptions for IBD-specific medications from 2011 to 2024.
Calculated healthcare expenditures using standard costs defined by the Catalan Department of Health.
Utilized autoregressive integrated moving average for forecasting costs up to 2034.
IBD-related healthcare expenditure increased from €67.4M in 2011 to €201.6M in 2024.
Per patient costs rose from €3,981 to €4,753 during the same period.
Biologic therapies accounted for the largest expenses, particularly for Crohn’s disease.
Forecasts predict total costs to reach €298.7M by 2034.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Population-based analysis highlights rising healthcare costs for inflammatory bowel disease in Catalonia, indicating future growth.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Brunet et al. (2026) studied this question.

synapsesocial.com/papers/69730f78c8125b09b0d1f4dd https://doi.org/10.1093/ecco-jcc/jjaf231.1482

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1TIME-trend and forecasting of the economic impact of inflammatory bowel disease in Catalonia: a population-based analysisOriginal Research · 2026
2P0195Factors associated with hospitalisations, emergency visits and related costs in inflammatory bowel disease: insights from the TrueColours-IBD digital monitoring programme in OxfordRandomized Controlled Trial · 2026
3DOP071Multi-omics biomarkers for predicting treatment response in inflammatory bowel diseaseRandomized Controlled Trial · 2026
4Prevalence, Incidence, Mortality and Trends in Treatment of Inflammatory Bowel Disease in Catalonia Between 2017 and 2023. An Epidemiological Update2025
5P0180Serum and urine metabolomic–lipoprotein signatures predict Inflammatory Bowel Disease treatment response to biologics and JAK-inhibitorsCohort Study · 2026

More related papers

P1347 Incidence and clinical impact of Campylobacter spp. Infection in patients with Inflammatory Bowel Disease2026
P0716Safety of biologic and small molecule therapies in IBD patients with previous cancer: risk of recurrence or new neoplasia2026
P0734Quality of life and mucosal healing in Ulcerative Colitis: CAVI_CU prospective study by GETECCU2026

More from Journal of Crohn s and Colitis

Plasma lipopolysaccharide-binding protein (LBP), a proxy for intestinal permeability, relates to clinicopathological and immunological disease activity in inflammatory bowel disease patients at diagnosis and during disease courseMon,
Targeting epithelial IFN-I signaling restores barrier integrity in anti-TNF refractory Crohn’s diseaseTue,